ImpediMed Releases Most Comprehensive Software Package for SOZO® Digital Health Platform

CARLSBAD, Calif., April 20, 2020 /PRNewswire/ — ImpediMed Restricted, a medical software program know-how firm that non-invasively measures, screens and manages fluid standing and tissue composition utilizing bioimpedance spectroscopy (BIS), at present introduced the discharge of its most complete software program package deal thus far for the SOZO® digital well being platform. This software program launch, designated as three.1, provides performance to SOZO for brand spanking new functions in coronary heart failure and finish stage renal illness sufferers whereas constructing on its present use as the one speedy, noninvasive FDA-cleared instrument to assist within the evaluation of subclinical lymphedema.

The software program package deal, which is offered as a no-cost improve to customers as a part of the ImpediMed SaaS mannequin, consists of the individually licensed HF-Dex™ coronary heart failure evaluation, a novel monitoring instrument for the evaluation of fluid overload in coronary heart failure sufferers that may assist present physicians invaluable data to risk-stratify sufferers in addition to to observe affected person situation and response to remedy. It additionally features a individually licensed evaluation module for sufferers with finish stage renal illness (ESRD) who’re present process dialysis. For these sufferers, SOZO offers an correct, noninvasive, goal approach to decide and monitor fluid ranges. ImpediMed has achieved CE Mark for the ESRD evaluation module as the corporate works with the FDA for a U.S. clearance.

“These new indications are a part of our growth of BIS know-how to carry the advantages of SOZO to new affected person populations,” mentioned Richard Carreon, Managing Director and CEO of ImpediMed. “Moreover, they replicate the ability of our SaaS mannequin. We are able to iterate shortly, reply to buyer suggestions and ship new options and instruments that assist healthcare professionals care for his or her sufferers. Whereas the SOZO know-how has nice utility, our major gross sales focus at present stays on increasing the attain and use of SOZO in most cancers facilities and surgical practices as a part of complete packages to forestall in addition to cease the development of lymphedema.”

SOZO helps physicians and care groups to forestall cancer-related lymphedema by calculating a affected person’s L-Dex® rating, a measure of extracellular fluid. One in three at-risk most cancers survivors will develop secondary lymphedema associated to their most cancers therapy. Most cancers Facilities throughout the globe are implementing ImpediMed’s SOZO know-how as a part of a Lymphedema Prevention Program. This includes the corporate’s advisable Check, Set off, Deal with™ protocol, which it developed together with physicians, for early detection and intervention with the aim of ending cancer-related lymphedema.

About ImpediMed
Based and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is a medical software program know-how firm that non-invasively measures, screens and manages fluid standing and tissue composition utilizing bioimpedance spectroscopy (BIS).

ImpediMed produces a household of FDA cleared and CE Marked medical units, together with SOZO® for a number of indications together with coronary heart failure, protein calorie malnutrition and lymphoedema, bought in choose markets globally.
For extra data, go to

Ahead-Trying Statements
This announcement comprises or could comprise forward-looking statements which can be based mostly on administration’s beliefs, assumptions and expectations and on data at present obtainable to administration.

All statements that tackle working efficiency, occasions or developments that we count on or anticipate will happen sooner or later are forward-looking statements, together with with out limitation our expectations with respect to our capacity to broaden gross sales and market acceptance within the US and Australia together with our estimates of potential revenues, prices, profitability and monetary efficiency; our capacity to develop and commercialise new merchandise together with our capacity to acquire reimbursement for our merchandise; our expectations with respect to our medical trials, together with enrolment in or completion of our medical trials and our related regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our mental property place.

Administration believes that these forward-looking statements are affordable as and when made. You shouldn’t place undue reliance on forward-looking statements as a result of they communicate solely as of the date when made. ImpediMed doesn’t assume any obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case. ImpediMed could not truly obtain the plans, projections or expectations disclosed in forward-looking statements. Precise outcomes, developments or occasions might differ materially from these disclosed within the forward-looking statements.

Media Contacts:

Ned Berkowitz and David Schull
Russo Companions
(646) 942-5629
[email protected]
[email protected]

SOURCE ImpediMed

Associated Hyperlinks

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *